Share on LinkedInShare on LinkedIn

ARTICLE · 12 DECEMBER 2014

Made In Canada Approach To "Pay For Delay": Bureau At Odds With US Approach

Cassels
Cassels
Contributor
Cassels

Cassels

Cassels Brock & Blackwell LLP is a Canadian law firm focused on serving the transaction, advocacy,...

View firm profile
Explore more from Cassels

AstraZeneca Plc’s payment to Ranbaxy Laboratories Ltd. to delay a generic version of heartburn medication Nexium was not unreasonably anticompetitive.

CanadaAntitrust/Competition Law

Last week, a US Federal Court ruled that AstraZeneca Plc’s payment to Ranbaxy Laboratories Ltd. to delay a generic version of heartburn medication Nexium was not unreasonably anticompetitive.

The decision confirmed the approach taken by the US Supreme Court in FTC v. Actavis, Inc.  that reverse-payment settlements (also known as “pay-for-delay” agreements) are subject to a “rule of reason” analysis (as opposed to being per se conspiracies). This is in contrast to the Canadian enforcement approach recently outlined by the Commissioner of Competition (the “Commissioner”), which left the door open to the application of the per se criminal conspiracy provision of the Competition Act of reverse-payment settlements.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from